热门资讯> 正文

Lyell Immunoglobulma报告第二季度结果

2025-08-13 05:06

Lyell Immunopharma press release (NASDAQ:LYEL): Q2 net loss of $42.7 million
Revenue of $8K, vs. $13K a year ago

More on Lyell Immunopharma

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Lyell Immunopharma announces up to $100 million equity private placement
Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments
Seeking Alpha’s Quant Rating on Lyell Immunopharma
Historical earnings data for Lyell Immunopharma

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。